The key changes in the 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) heart failure (HF) guidelines include updated staging of HF, and recommendations on treatments such as sodium glucose cotransporter-2 inhibitor (SGLT2i), mineralocorticoid receptor antagonists (MRA), and angiotensin receptor-neprilysin inhibitors (ARNIs), especially in HF with mildly reduced ejection fraction (HFmrEF) and HF with preserved ejection fraction (HFpEF). |
There are minimal differences between the 2022 ACC/AHA/HFSA HF guideline and the 2021 European Society of Cardiology (ESC) HF guideline, although the key differences in staging and medication recommendation come from the time difference of publication. |
Introduction
Evaluation and Diagnosis of HF
Recommendation | ACC/AHA/HFSA | ESC |
---|---|---|
Initial investigations | ||
For patients who are diagnosed with HF, laboratory evaluation should include full blood count, urinalysis, serum electrolytes, blood urea nitrogen, serum creatinine, glucose and HbA1c, lipid profile, liver function tests, iron studies, and thyroid-stimulating hormone to optimize management | 1 | 1 |
For all patients with HF, a 12-lead ECG should be performed | 1 | 1 |
BNP or NT-proBNP | ||
Patients presenting with dyspnea | 1 | |
In patients with chronic HF for risk stratification | 1 | 1 |
In patients hospitalized with HF to establish prognosis | 1 | |
In patients at risk of developing HF, BNP can be used as a screening tool followed by team-based care to prevent development of LV dysfunction or new-onset HF | 2a | |
A pre-discharge BNP can be useful to inform the trajectory of the patient and establish a postdiagnosis prognosis | 2a | |
Genetic testing | ||
In first-degree relatives of selected patients with genetic or inherited cardiomyopathies for early detection and prompt management | 1 | |
In patients with nonischemic cardiomyopathy | 2a | |
Chest X-ray | ||
Suspected or new-onset HF, or those presenting with acute decompensated HF | 1 | 1 |
TTE | ||
During initial evaluation of suspected or newly diagnosed HF | 1 | 1 |
In patients with HF who have significant clinical change, or who have received GDMT and are being considered for invasive procedures or device therapy | 1 | |
If TTE is inadequate, alternative imaging (e.g., CMR, cardiac CT, radionucleotide imaging) is recommended for the assessment of LVEF | 1 | 1 |
CMR | ||
In patients with HF or cardiomyopathy, CMR can be useful for diagnosis and management | 2a | |
For the characterization of myocardial tissue in suspected infiltrative disease, Fabry disease, inflammatory disease, LV non-compaction, amyloid, sarcoidosis, iron overload | 1 | |
Cardiopulmonary exercise testing | ||
In selected ambulatory patients to determine appropriateness of advanced treatments (e.g., LV assist device, heart transplant) | 1 | 1 |
In ambulatory patients to assess functional capacity | 2a | |
In ambulatory patients to assess cause of dyspnea | 2a | 2a |
Invasive evaluation | ||
Endomyocardial biopsy may be useful when specific diagnosis is suspected that would influence therapy | 2a | 2a |
Right heart catheterization in selected patients with HF with persistent or worsening symptoms, signs, diagnostic parameters, and in whom hemodynamics are uncertain | 2a | |
Right heart catheterization in patients with severe HF being evaluated for heart transplant or mechanical circulatory support | 1 | |
Other imaging | ||
In patients with HF, an evaluation for possible ischemic heart disease can be useful to identify the cause and guide management | 2a | |
In patients with HF and CAD who are candidates for coronary revascularization, non-invasive stress imaging may be considered for detection of myocardial ischemia to help guide coronary revascularization | 2b | 2b |
No imaging | ||
In patients with HF in the absence of: (1) clinical status change, (2) treatment interventions that might have a significant effect on cardiac function, or (3) candidacy for invasive procedures or device therapy, routine repeat assessment of LV function is not indicated | 3 |
-
Electrocardiogram (ECG)
-
Blood tests: Natriuretic peptides, serum urea and electrolytes, creatinine, full blood count, lipid profile, iron studies, liver and thyroid function tests are recommended to differentiate HF from other conditions, provide prognostic information, and guide potential therapy.
-
Transthoracic echocardiography (TTE): This aids in determining the left ventricular ejection fraction (LVEF) and identifying the underlying etiology of HF.
-
Chest X-ray: This provides supportive evidence of HF and aids in ruling out alternative causes of breathlessness.
Cardiac Magnetic Resonance (CMR)
Investigating for Underlying Coronary Artery Disease
Endomyocardial Biopsy
Definition/Staging
Stage | Definition |
---|---|
A | Patients at risk for HF but without current or previous symptoms/signs of HF and without structural/functional heart disease or abnormal biomarkers. This includes patients with hypertension, cardiovascular disease, diabetes, obesity, exposure to cardiotoxic agents, genetic variant cardiomyopathy, or a family history of cardiomyopathy |
B | Patients without current signs or previous symptoms/signs of HF but evidence of one of the following: Structural heart disease Evidence of increased filling pressures Risk factors and Increased natriuretic peptide levels or Persistently elevated cardiac troponin |
C | Patients with current or previous symptoms/signs of HF |
D | Marked HF symptoms that interfere with daily life and with recurrent hospitalizations despite attempts to optimize GDMT |
Type of HF according to LVEF | ACC/AHA/HFSA 2022 criteria | ESC 2021 criteria |
---|---|---|
HFrEF | LVEF ≤ 40% | LVEF ≤ 40% |
HFimpEF | Previous LVEF ≤ 40% and a follow-up LVEF > 40% | N/A |
HFmrEF | LVEF 41–49% Evidence of spontaneous or provokable increased LV filling pressures (e.g., elevated natriuretic peptide, noninvasive and invasive hemodynamic measurement) | LVEF 41–49% |
HFpEF | LVEF ≥ 50% Evidence of spontaneous or provokable increased LV filling pressures (e.g., elevated natriuretic peptide, noninvasive and invasive hemodynamic measurement) | LVEF ≥ 50% Objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures, including raised natriuretic peptides |
Stage A: Patients at Risk for HF
Diet, Exercise, and Blood Pressure Recommendations
SGLT2i Therapy in Patients with Diabetes
Stage B: Patients with Pre-HF
Stage C: Symptomatic HF
Non-pharmacological Management
Pharmacotherapy for Patients with HFREF
Medication | Side effect |
---|---|
ACEi | Hypotension Cough Hyperkalemia Renal impairment Angioedema Rash Abnormal LFTs |
ARB | First-dose hypotension Hyperkalemia Diarrhea Dyspepsia Renal impairment Nasal congestion Hypersensitivity reactions Abnormal LFTs |
ARNi | Hyperkalemia Raised serum creatinine ± renal impairment Hypotension Cough Anemia Angioedema |
Beta-blocker | Bradycardia Orthostatic hypotension Transient worsening of heart failure Bronchospasm Rare: heart block, impotence, hypersensitivity, thrombocytopenia, abnormal LFTs |
MRA | Hyperkalemia Hyponatremia + hypochloremia Nausea and vomiting Gastrointestinal cramps and diarrhea Gynecomastia Menstrual irregularities Renal impairment Rare: agranulocytosis, hepatotoxicity, cutaneous vasculitis |
SGLT2i | Genital infections UTI Dyslipidemia Hypoglycemia (when used with sulfonylurea or insulin) Increased hematocrit Increased serum creatinine (related to volume depletion, reversible) Volume depletion (hypotension, dehydration) Euglycemic ketoacidosis Rare: perineal necrotizing fasciitis |
Digoxin | Anorexia, nausea, and vomiting Blurred vision Bradycardia Rash ECG changes – shortened QRS complexes, atrial or ventricular extrasystoles, paroxysmal atrial tachycardia with AV block, ventricular tachycardia or fibrillation, heart block Rare: thrombocytopenia, seizures, psychosis |
Ivabradine | Transient areas of enhanced brightness in the visual field Bradycardia Ventricular extrasystoles |
Vericiguat | Hypotension Anemia Nausea, vomiting, and dyspepsia Headache |
RAAS Inhibition
Beta Blockade
MRAs
SGLT2i
Other Pharmacotherapeutic Options
Diuretics
Device Therapy
Multidisciplinary Team Involvement
Telemonitoring
HFmrEF Management
HFpEF Management
Stage D: Advanced HF
Palliative Care
Conclusions
ACC/AHA/HFSA | ESC |
---|---|
Staging | |
Differentiation between stages A and B, with clear recommendations for each stage | Recommendations for patients ‘at risk’ |
Investigations | |
CMR imaging can be useful for non-ischemic cardiomyopathy but would not be recommended routinely unless suggested to be necessary from TTE and clinical findings | CMR imaging for characterization of myocardial tissue in suspected infiltrative disease, Fabry disease, inflammatory disease (e.g., myocarditis), LV non-compaction, amyloid, sarcoidosis, and hemochromatosis |
Management of HFrEF | |
Stronger recommendation for hydralazine/isosorbide mononitrate in self-reported Black people | |
Stronger recommendation of ICD for primary prevention in non-ischemic heart failure | |
Management of HFmrEF | |
SGLT2i recommended | |
Management of HFimpEF | |
Only considered in ACC/AHA/HFSA guideline | |
Management of HFpEF | |
SGLT2i, ARNi (or ACEi/ARB), MRA for management of HFpEF | Diuretics and optimal management of comorbidities |
Other | |
Formal recommendation for palliative care | |
Formal recommendation for telemonitoring |